Nature's Phase Zero Trials

A look into the strategic intelligence offered by polyubiquitination disorders that can give your portfolio a decisive edge

The search for validated, high-impact targets is a defining challenge for our industry. We spend billions navigating the valley of death, moving from preclinical models to human trials, often with a low probability of success. I propose a shift in perspective. We must look to a unique set of human "experiments of nature" that provide an unparalleled strategic roadmap: the primary disorders of polyubiquitination.

These are not merely rare diseases. They are exquisite human proof-of-concept models. Caused by monogenic defects in the enzymes that control protein ubiquitination, these conditions reveal, with incredible precision, the consequences of removing or hyperactivating a single node in a critical signaling network. They offer us a blueprint, de-risking target selection and illuminating pathways with a clarity that no animal model can replicate. The clinical outcomes in these patients—spanning severe autoinflammation to profound immunodeficiency—are not just tragic medical cases; th…